Uses of Gourcuff-5

Gourcuff-5 is a medicine to treat benign prostatic hypertrophy, which helps to enlarge the ureteral tube, thereby helping the patient to urinate easily. To understand more about the use of Gourcuff-5, please refer to the following article.

Gourcuff-5 drug whose main ingredient is Alfuzosin HCl is used in the treatment of benign prostatic hypertrophy. Each film-coated tablet Gourcuff-5 contains
Alfuzosin HCI 5mg Excipients: Lactose monohydrate, M101 microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, HPMC E6, titanium dioxide, talc, polyethylene glycol 4000, polysorbate 80 and oil Castor. Dosage form: Film coated tablets. Alfuzosin is a quinoline derivative and a selective antagonist of postsynaptic alpha-1-adrenergic receptors.
Long-acting (slow-release) forms include:
Absorption: Maximum plasma concentrations are reached approximately 3 hours after oral administration. The elimination half-life is approximately 8 hours. Bioavailability is also reduced on average by about 15% compared with Xatral 2.5mg tablets. This decrease was also compensated by increasing the daily dose of Xatral SR 5mg tablets. In the elderly, the absorption of alfuzosin is faster and the maximum concentration is higher. Bioavailability may be increased and a decrease in volume of distribution has been reported in a few patients. Distribution: The amount of alfuzosin bound to plasma proteins is 90%. It is also extensively metabolised and excreted mainly in the bile and feces. For patients with renal failure on dialysis or not, the volume of distribution and clearance of alfuzosin is increased due to increased free fraction. Metabolism: No normally active metabolites have been found in humans. Elimination: Alfuzosin is also extensively metabolised and excreted mainly in bile and feces. The major elimination half-life is 8 hours. Chronic renal failure, even with severe renal impairment (creatinine clearance 15 to 40 ml/min) will not be aggravated by alfuzosin. In chronic heart failure, the pharmacokinetic properties of alfuzosin are not altered.

What disease does Gourcuff-5 medicine treat? Gourcuff-5 is also prescribed for functional symptomatic treatment in patients with benign prostatic hypertrophy.
Uses of Alfuzosin HCl in the main formula is an oral derivative of Quinazolin that has selective alpha 1 - adrenergic antagonism in the lower urinary tract, prostate, fundus, bladder and urethra.
Compared with drugs of the same class, such as Prazosin, Tamsulosin, Doxazosin, Terazoxin, Alfuzosin is more effective because:
Selective on receptors for the lower urinary tract than blood vessels, so it effectively reduces urethral resistance with little effect on blood pressure. Lower urinary tract selectivity is not affected by age. Highest selectivity to vascular prostate tissue. The mechanism of action of the drug Gourcuff-5:
Relaxes prostate smooth muscle and relieves obstruction in the bladder neck (reduces contraction pressure at the bladder cone) and reduces urethral pressure thereby increasing the volume of the bladder. Accumulation of urine causes a feeling of needing to urinate and a decrease in the volume of urine remaining in the bladder after urinating. The drug also reduces irritation and reduces obstruction to the flow of urine. Alfuzosin will increase urine flow by 30% at first treatment in patients with benign prostatic hypertrophy whose urine flow is 15ml/sec. In addition, Alfuzosin is also being studied for its effect on reducing ureteral stones.

During use reports of adverse effects that patients may experience with different frequencies.
Respiratory: Rhinitis, sinusitis, bronchitis, pharyngitis and upper respiratory tract infection. Gastrointestinal disorders: Nausea, abdominal pain and diarrhea. Nervous system: Headache, dizziness, dizziness and fainting. Urogenital - Genitourinary Impotence. In addition, patients should also note a few problems when using the drug as follows:
Do not combine alfuzosin with other alpha-blocker antihypertensive drugs such as prazosin, terazosin, because it can cause hypotension. standing posture is very heavy. Caution should be exercised when alfuzosin is co-administered with other antihypertensive agents, as the risk of excessive hypotension may be increased. Drugs that inhibit the cytochrome P450 isoenzyme CYP3A4 activity, such as ketoconazole, itraconazole, ritonavir, may increase blood levels of alfuzosin. Atenolol when used concomitantly with alfuzosin may increase plasma concentrations of both drugs. Diltiazem when used concomitantly with alfuzosin may increase plasma concentrations of both drugs. Cimetidine may increase the plasma concentration of alfuzosin.

4.1. Usage Take orally. Dosage is also calculated in terms of alfuzosin HCl. The first dose should be taken at night before going to bed. Swallow the tablet whole with plenty of water. Do not break and crush or chew the tablet. This may affect the release of the drug inside the body. 4.2. Dosage The dose of the drug will be calculated in the form of Alfuzosin HCl. Patients use the dose prescribed by the doctor or as recommended below:
Usual dose: 2.5mg (1⁄2 tablets)/time x 3 times/day. The maximum dose that can be reached is 10mg/day. The elderly or are taking blood pressure medication, people with kidney failure. Initial dose: 2.5mg (1⁄2 tablets)/time x 2 times/day. Increase the dose according to the patient's response. Patients with mild and moderate hepatic impairment: Initial dose is: 2.5mg (1⁄2 tablets)/time/day. Increase dose according to patient response but maximum dose will be 2.5mg (1⁄2 tablets)/time x 2 times/day. If you miss a dose, take it as soon as you remember. However, skip the missed dose if it is almost time for your next dose and take the scheduled dose. Do not take a double dose to make up for the missed dose.

Elderly: While there are no differences in efficacy or safety between the elderly and young adults, and there is no evidence of age-related differences, it is not excluded that some Elderly people may be more sensitive to the drug. Hepatic Impairment: In severe hepatic impairment, the half-life is longer, and bioavailability is also increased compared to healthy volunteers.
Patients with renal impairment: For patients with renal impairment, whether dialysis is required or not, the volume of distribution and clearance of the drug is increased due to an increase in the free drug fraction. Does not make chronic kidney failure worse.
Patients with heart failure: For patients with chronic heart failure, the pharmacokinetic properties of the drug are unchanged.
Above is important information on how to use Gourcuff-5. Hopefully with the above sharing will help the process of drug use in patients more effective and accurate.